Standard Lithium Ltd. press release

BELLUS Health to Present at Bloom Burton & Co. Healthcare Investor Conference

2014-06-11

TSXV - TSX Venture Exchange · Lithium · Bromine · Potash · Sodium · Canada

##

LAVAL, QC, June 11, 2014/CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a drug development company focused on rare diseases, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present an update on the Company's progress at the Bloom Burton & Co. Healthcare Investor Conference at the TorontoBoard of Trade on June 18, 2014at 3:30 p.m. EDTin Toronto.

BELLUS Health's corporate presentation will be available on the Company's website at www.bellushealth.comfollowing the presentation.

Bloom Burton's third annual healthcare investor conference features Canada'spremier publicly-traded and venture-backed private companies. The event will attract Canadian, U.S. and European investors who are interested in the latest developments in Canadian healthcare companies.

About BELLUS Health (www.bellushealth.com)

BELLUS Health is a drug development company focused on rare diseases. It has a portfolio of rare disease projects including KIACTA™ in Phase III for AA amyloidosis, KIACTA™ for sarcoidosis, clinical stage ShigamabTMfor STEC-related Hemolytic Uremic Syndrome (sHUS), and a research-stage project for AL amyloidosis. The lead program KIACTA™ is currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics.

SOURCE BELLUS Health Inc.

Adam Peeler TMX Equicom 416-815-0700 ext. 225 |apeeler@tmxequicom.com

Copyright CNW Group 2014